These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 7493356

  • 1. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression.
    DeNardo SJ, Gumerlock PH, Winthrop MD, Mack PC, Chi SG, Lamborn KR, Shen S, Miers LA, deVere White RW, DeNardo GL.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5837s-5841s. PubMed ID: 7493356
    [Abstract] [Full Text] [Related]

  • 2. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
    Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL.
    Cancer Res; 2002 Aug 01; 62(15):4263-72. PubMed ID: 12154028
    [Abstract] [Full Text] [Related]

  • 3. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.
    Denardo SJ, Richman CM, Kukis DL, Shen S, Lamborn KR, Miers LA, Kroger LA, Perez EA, Denardo GL.
    Anticancer Res; 1998 Aug 01; 18(6A):4011-8. PubMed ID: 9891439
    [Abstract] [Full Text] [Related]

  • 4. Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.
    DeNardo SJ, Kukis DL, Miers LA, Winthrop MD, Kroger LA, Salako Q, Shen S, Lamborn KR, Gumerlock PH, Meares CF, DeNardo GL.
    J Nucl Med; 1998 May 01; 39(5):842-9. PubMed ID: 9591587
    [Abstract] [Full Text] [Related]

  • 5. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

  • 6. Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.
    DeNardo GL, Kroger LA, Meares CF, Richman CM, Salako Q, Shen S, Lamborn KR, Peterson JJ, Miers LA, Zhong GR, DeNardo SJ.
    Clin Cancer Res; 1998 Oct 01; 4(10):2483-90. PubMed ID: 9796981
    [Abstract] [Full Text] [Related]

  • 7. Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts.
    Ng B, Kramer E, Liebes L, Wasserheit C, Hochster H, Blank E, Ceriani R, Furmanski P.
    Cancer Res; 2001 Apr 01; 61(7):2996-3001. PubMed ID: 11306478
    [Abstract] [Full Text] [Related]

  • 8. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
    Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ.
    Cancer Res; 1999 Mar 15; 59(6):1347-55. PubMed ID: 10096569
    [Abstract] [Full Text] [Related]

  • 9. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts.
    Gerretsen M, Visser GW, van Walsum M, Meijer CJ, Snow GB, van Dongen GA.
    Cancer Res; 1993 Aug 01; 53(15):3524-9. PubMed ID: 8339258
    [Abstract] [Full Text] [Related]

  • 10. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.
    J Nucl Med; 2004 Feb 01; 45(2):327-37. PubMed ID: 14960657
    [Abstract] [Full Text] [Related]

  • 11. Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy.
    Kroger LA, DeNardo GL, Gumerlock PH, Xiong CY, Winthrop MD, Shi XB, Mack PC, Leshchinsky T, DeNardo SJ.
    Cancer Biother Radiopharm; 2001 Jun 01; 16(3):213-25. PubMed ID: 11471486
    [Abstract] [Full Text] [Related]

  • 12. Effect of multiple, repeated doses of radioimmunotherapy on target antigen expression (breast MUC-1 mucin) in breast carcinomas.
    Peterson JA, Blank EW, Ceriani RL.
    Cancer Res; 1997 Mar 15; 57(6):1103-8. PubMed ID: 9067279
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer.
    Cardillo TM, Ying Z, Gold DV.
    Clin Cancer Res; 2001 Oct 15; 7(10):3186-92. PubMed ID: 11595713
    [Abstract] [Full Text] [Related]

  • 14. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.
    DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA, DeNardo DG, Meares CF, DeNardo GL.
    Proc Natl Acad Sci U S A; 1997 Apr 15; 94(8):4000-4. PubMed ID: 9108094
    [Abstract] [Full Text] [Related]

  • 15. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [Abstract] [Full Text] [Related]

  • 16. Selection of tumor-specific epitopes on target antigens for radioimmunotherapy of breast cancer.
    Peterson JA, Couto JR, Taylor MR, Ceriani RL.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5847s-5851s. PubMed ID: 7493358
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice.
    O'Donnell RT, DeNardo SJ, DeNardo GL, Miers L, Lamborn KR, Kukis DL, Meyers FJ.
    Prostate; 2000 Aug 01; 44(3):187-92. PubMed ID: 10906734
    [Abstract] [Full Text] [Related]

  • 18. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [Abstract] [Full Text] [Related]

  • 19. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
    Denardo SJ, Richman CM, Goldstein DS, Shen S, Salako Q, Kukis DL, Meares CF, Yuan A, Welborn JL, Denardo GL.
    Anticancer Res; 1997 Oct 01; 17(3B):1735-44. PubMed ID: 9179227
    [Abstract] [Full Text] [Related]

  • 20. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
    Buchsbaum D, Khazaeli MB, Liu T, Bright S, Richardson K, Jones M, Meredith R.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.